Chemed (CHE)
(Delayed Data from NYSE)
$554.37 USD
+6.21 (1.13%)
Updated May 31, 2024 04:00 PM ET
After-Market: $555.31 +0.94 (0.17%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$554.37 USD
+6.21 (1.13%)
Updated May 31, 2024 04:00 PM ET
After-Market: $555.31 +0.94 (0.17%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
Zacks News
Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ABIOMED's (ABMD) fiscal fourth-quarter performance is likely to reflect growth in Impella product line.
Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.
5 Top Growth Stocks to Buy Ahead of Q1 Earnings This Month
by Nalak Das
Five growth stocks with a favorable Zacks Rank that are set to beat first-quarter earnings estimates this month.
Cerner (CERN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.
3 Reasons Why Chemed (CHE) Is a Great Growth Stock
by Zacks Equity Research
Chemed (CHE) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow
by Zacks Equity Research
On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.
5 Healthcare Stocks Poised to Beat Earnings Estimates in Q1
by Zacks Equity Research
Earnings results of healthcare sector are likely to reflect solid demand for its products and services from aging population and the growing incidence of COVID-19 illness.
Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.
Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results
by Nalak Das
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) successfully attains EUA from the FDA as well as receives the CE Mark in Europe for its COVID-19 diagnostic test.
Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical (ISRG) first-quarter results benefit from strong growth across all businesses and higher revenues.
Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts
by Zacks Equity Research
To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.
Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance
by Zacks Equity Research
Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.
New Strong Buy Stocks For April 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) Q1 earnings are likely to reflect better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth.
Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) recently-launched COVID-19 test service anticipated to have contributed to Q1 revenues.
Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?
by Zacks Equity Research
Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.